<!DOCTYPE html>
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta content="SAS 9.4" name="generator"/>
<title>SAS Output</title>
<style>
/*<![CDATA[*/
.body.c > table, .body.c > pre, .body.c div > table,
.body.c div > pre, .body.c > table, .body.c > pre,
.body.j > table, .body.j > pre, .body.j div > table,
.body.j div > pre, .body.j > table, .body.j > pre,
.body.c p.note, .body.c p.warning, .body.c p.error, .body.c p.fatal,
.body.j p.note, .body.j p.warning, .body.j p.error, .body.j p.fatal,
.body.c > table.layoutcontainer, .body.j > table.layoutcontainer { margin-left: auto; margin-right: auto }
.layoutregion.l table, .layoutregion.l pre, .layoutregion.l p.note,
.layoutregion.l p.warning, .layoutregion.l p.error, .layoutregion.l p.fatal { margin-left: 0 }
.layoutregion.c table, .layoutregion.c pre, .layoutregion.c p.note,
.layoutregion.c p.warning, .layoutregion.c p.error, .layoutregion.c p.fatal { margin-left: auto; margin-right: auto }
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r p.warning, .layoutregion.r p.error, .layoutregion.r p.fatal { margin-right: 0 }
article, aside, details, figcaption, figure, footer, header, hgroup, nav, section { display: block }
html{ font-size: 100% }
.body { margin: 1em; font-size: 13px; line-height: 1.231 }
sup { position: relative; vertical-align: baseline; bottom: 0.25em; font-size: 0.8em }
sub { position: relative; vertical-align: baseline; top: 0.25em; font-size: 0.8em }
ul, ol { margin: 1em 0; padding: 0 0 0 40px }
dd { margin: 0 0 0 40px }
nav ul, nav ol { list-style: none; list-style-image: none; margin: 0; padding: 0 }
img { border: 0; vertical-align: middle }
svg:not(:root) { overflow: hidden }
figure { margin: 0 }
table { border-collapse: collapse; border-spacing: 0 }
.layoutcontainer { border-collapse: separate; border-spacing: 0 }
p { margin-top: 0; text-align: left }
h1.heading1 { text-align: left }
h2.heading2 { text-align: left }
h3.heading3 { text-align: left }
h4.heading4 { text-align: left }
h5.heading5 { text-align: left }
h6.heading6 { text-align: left }
span { text-align: left }
table { margin-bottom: 1em }
td, th { text-align: left; padding: 3px 6px; vertical-align: top }
td[class$="fixed"], th[class$="fixed"] { white-space: pre }
section, article { padding-top: 1px; padding-bottom: 8px }
hr.pagebreak { height: 0px; border: 0; border-bottom: 1px solid #c0c0c0; margin: 1em 0 }
.stacked-value { text-align: left; display: block }
.stacked-cell > .stacked-value, td.data > td.data, th.data > td.data, th.data > th.data, td.data > th.data, th.header > th.header { border: 0 }
.stacked-cell > div.data { border-width: 0 }
.systitleandfootercontainer { white-space: nowrap; margin-bottom: 1em }
.systitleandfootercontainer > p { margin: 0 }
.systitleandfootercontainer > p > span { display: inline-block; width: 100%; white-space: normal }
.batch { display: table }
.toc { display: none }
.proc_note_group, .proc_title_group { margin-bottom: 1em }
p.proctitle { margin: 0 }
p.note, p.warning, p.error, p.fatal { display: table }
.notebanner, .warnbanner, .errorbanner, .fatalbanner,
.notecontent, .warncontent, .errorcontent, .fatalcontent { display: table-cell; padding: 0.5em }
.notebanner, .warnbanner, .errorbanner, .fatalbanner { padding-right: 0 }
.body > div > ol li { text-align: left }
.beforecaption > h4 { margin-top: 0; margin-bottom: 0 }
.c { text-align: center }
.r { text-align: right }
.l { text-align: left }
.j { text-align: justify }
.d { text-align: right }
.b { vertical-align: bottom }
.m { vertical-align: middle }
.t { vertical-align: top }
.accessiblecaption {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.aftercaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.batch > col, .batch > colgroup > col, .batch > colgroup, .batch > tr, .batch > * > tr, .batch > thead, .batch > tbody, .batch > tfoot { border: none; }
.batch {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    padding: 7px;
    }
.beforecaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.body {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    margin-left: 8px;
    margin-right: 8px;
}
.bodydate {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    text-align: right;
    vertical-align: top;
    width: 100%;
}
.bycontentfolder {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.byline {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.bylinecontainer > col, .bylinecontainer > colgroup > col, .bylinecontainer > colgroup, .bylinecontainer > tr, .bylinecontainer > * > tr, .bylinecontainer > thead, .bylinecontainer > tbody, .bylinecontainer > tfoot { border: none; }
.bylinecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.caption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.cell, .container {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.contentfolder, .contentitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.contentproclabel, .contentprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.contents {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.contentsdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.contenttitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.continued {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    width: 100%;
}
.data {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.dataemphasis {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataemphasisfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataempty {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datafixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datastrong {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.datastrongfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.date {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.document, .errorbanner, .errorcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.errorcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.extendedpage {
    background-color: #ffffff;
    border-style: solid;
    border-width: 1pt;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
    text-align: center;
}
.fatalbanner, .fatalcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.fatalcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.folderaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footer {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.frame {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.graph > col, .graph > colgroup > col, .graph > colgroup, .graph > tr, .graph > * > tr, .graph > thead, .graph > tbody, .graph > tfoot { border: none; }
.graph {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.header {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.headersandfooters, .headerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.index, .indexaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.indexitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.indexprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.indextitle, .linecontent, .list, .list10, .list2, .list3, .list4, .list5, .list6, .list7, .list8, .list9, .listitem, .listitem10, .listitem2, .listitem3, .listitem4, .listitem5, .listitem6, .listitem7, .listitem8, .listitem9, .note, .notebanner, .notecontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.notecontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.output > col, .output > colgroup > col, .output > colgroup, .output > tr, .output > * > tr, .output > thead, .output > tbody, .output > tfoot { border: none; }
.output {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.pageno {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    text-align: right;
    vertical-align: top;
}
.pages {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.pagesdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.pagesitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.pagesproclabel, .pagesprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.pagestitle, .paragraph {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.parskip {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.prepage, .proctitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.proctitlefixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooter {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooteremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooteremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooterempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowfooterstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheader {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderemphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderemphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowheaderstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.systemfooter, .systemfooter10, .systemfooter2, .systemfooter3, .systemfooter4, .systemfooter5, .systemfooter6, .systemfooter7, .systemfooter8, .systemfooter9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: bold;
}
.systemtitle, .systemtitle10, .systemtitle2, .systemtitle3, .systemtitle4, .systemtitle5, .systemtitle6, .systemtitle7, .systemtitle8, .systemtitle9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: medium;
    font-style: normal;
    font-weight: bold;
}
.systitleandfootercontainer > col, .systitleandfootercontainer > colgroup > col, .systitleandfootercontainer > colgroup, .systitleandfootercontainer > tr, .systitleandfootercontainer > * > tr, .systitleandfootercontainer > thead, .systitleandfootercontainer > tbody, .systitleandfootercontainer > tfoot { border: none; }
.systitleandfootercontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.table > col, .table > colgroup > col, .table > colgroup, .table > tr, .table > * > tr, .table > thead, .table > tbody, .table > tfoot { border: none; }
.table {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.titleandnotecontainer > col, .titleandnotecontainer > colgroup > col, .titleandnotecontainer > colgroup, .titleandnotecontainer > tr, .titleandnotecontainer > * > tr, .titleandnotecontainer > thead, .titleandnotecontainer > tbody, .titleandnotecontainer > tfoot { border: none; }
.titleandnotecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.titlesandfooters, .usertext, .warnbanner, .warncontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.warncontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
/*]]>*/
</style>
</head>
<body class="c body">
<div style="padding-bottom: 8px; padding-top: 1px">
<div id="IDX" class="systitleandfootercontainer" style="border-spacing: 1px">
<p><span class="c systemtitle">Micro RNA data set 2</span> </p>
</div>
<div style="padding-bottom: 8px; padding-top: 1px">
<table class="table" style="border-spacing: 1px" aria-label="Data Set REF.MICRO_RNA_SORTED_2">
<caption aria-label="Data Set REF.MICRO_RNA_SORTED_2"></caption>
<colgroup><col/><col/><col/></colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="header" scope="col">Title</th>
<th class="header" scope="col">Main_Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="data">The role of miR-320 in glucose and lipid metabolism disorder-associated diseases</td>
<td class="data">Although glucose and lipid metabolism disorder-associated diseases have been recognized for many years, the effective prevention and treatment strategies remain elusive. In this article, we first reviewed that miR-320 might be a potential biomarker for metabolic diseases, such as obesity, diabetes, and its complications, which provided a new diagnostic strategy for these diseases. Then, we systematically described the effects of miR-320 on glucose and lipid metabolism disorder-associated diseases. For clinical application, multiple studies suggested that the aberrant expression of miRNAs played essential roles in various diseases, which provided a new therapeutic strategy [149]. Here, we reviewed the diagnostic and therapeutic strategies for glucose and lipid metabolism disorder-associated diseases by targeting miR-320. Moreover, we provided a summary table to better illustrate the various miRNAs indicated in the text (Table 1).  XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="data">Micro-ribonucleic acid-23a-3p prevents the onset of type 2 diabetes mellitus by suppressing the activation of nucleotide-binding oligomerization-like receptor family pyrin domain containing 3 inflammatory bodies-caused pyroptosis through negatively regulating NIMA-related kinase 7</td>
<td class="data">Type 2 diabetes mellitus is a growing worldwide healthcare burden, and is tightly associated with the widespread prevalence of obesity (17). It is the consequence of disrupted insulin secretion and resistance, and can also be described as an imbalance of carbohydrate, protein and lipid metabolisms (17). Over the recent
decades of investigations, the understanding of type 2 diabetes mellitus has been developing and making progress expeditiously. However, it is a complicated chronic condition that demands perpetual healthcare, together with the necessity of patient self-care for monitoring aberrant glucose level fluctuations, both making it a disorder that generates a burden for healthcare. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore, studies aiming to develop and improve more effective and safer treatments are at of importance. miRNAs are short non-coding RNAs (17–24 nucleotides) that bind to the 3&apos;UTRs of targeted messenger RNAs to modulate gene expression by translational suppression or degradation (10). miRNAs have been discovered to regulate metabolisms correlated with type 2 diabetes mellitus (18), including the insulin pathway and glucose homeostasis, emphasizing their feasibility as therapeutic targets in treating obesity and metabolic disorders. The plasma of patients with cardiovascular diseases has been observed to carry inhibited expression of miR-2319, and some research has shown that miR-23 plays a role in glucose metabolism in dog muscles (20). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, we identified that the expression of miR-23a-3p and NEK7 was negatively correlated in patients and rat models with type 2 diabetes mellitus; more specifically, miR-23a-3p is downregulated, whereas NEK7 is upregulated. With the prediction functionality of TargetScan software in predicting the presence of a targeted binding site between miR-23a-3p and NEK7 3&apos;UTR, we have proved that miR-23a-3p negatively regulates NEK7 expression by binding to its 3&apos;UTR region. This negative regulation affects the expression of NLRP3 inflammatory bodies, which is also consistent with another finding that NEK7 regulates the activation of NLRP3 inflammatory bodies (21). XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recent studies have shed light on novel forms of programmed cell death, such as necroptosis and pyroptosis. Pyroptosis is a pro-inflammatory form of programmed cell death that depends on the enzymatic function of inflammatory proteases that are part of cysteine-dependent aspartate-specific caspase family (22). Pyroptosis has been mostly reported to occur in phagocytes of the myeloid lineage, including neutrophils, macrophages and dendritic cells, epithelial cells, endothelial cells, and neurons. One underlying potential mechanism is that the aforementioned cells show higher expression levels of inflammatory caspases that could promote pyroptosis, such as caspase-122. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Inflammasomes are multimeric (a protein composed of several subunits) protein structures that govern inflammatory reactions and pyroptosis as part of a host’s defenses to prevent microbial invasion (23). The sensors of inflammasomes are closely related to apoptosis-associated speck-like protein, which contains an apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain, could trigger inflammatory caspase-1 to allow the secretion of inflammatory cytokines and initiate programmed cell death to enable the host with the defensive responses in fighting pathogens (23). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The capability of NLRs to construct inflammasomes was originally attributed to the NLF-family pyrin domain-containing 1 (NLRP1) (24,25). It has also been reported that the increased production of reactive oxygen species and thiol oxidation could stimulate NEK7-dependent NLRP3 activation, and that a decrease in NADH level and mitochondrial reactive oxygen species level results in the dysregulation of cellular glycolytic flux that would further promote NLRP3 inflammasomes and pyroptosis (26,27). In addition, we found that miR-23a-3p inhibits pyroptosis through the inactivation of NEK7 / NLRP3 inflammatory bodies, which have been verified by overexpressing miR-23a-3p, depleting miR-23a-3p or depleting NEK7 experiment, as shown. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  CONCLUSIONS =&gt; In brief, we have provided evidence that miR-23a-3p could target NEK7 to further inhibit the activation of NLRP3, which suppressed pyroptosis. Hence, the symptoms of type 2 diabetes mellitus in rats could be mitigated (Figure 6). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="data">miR-192 is upregulated in T1DM, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing GLP-1 expression</td>
<td class="data">T1DM is an insulin‑dependent type of diabetes (1). One of the key patho-physiological mechanisms of T1DM is the autoimmune‑mediated destruction of pancreatic β‑cells with consequent severe insulin deficiency (2‑5). miR‑192 has been identified to have several key roles in diabetic kidney disease (33); however, the detailed functions of miR‑192 in T1DM have remained to be elucidated. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present study revealed that miR‑192 was upregulated in T1DM patients and STZ‑induced rats. Furthermore, insulin treatment had no effect on the expression of miR‑192 in STZ‑induced rats. In addition, the expression of miR‑192 was closely associated with age and high glucose levels. To further assess the effect of miR‑192 in T1DM, the pancreatic β cell line NIT‑1 was used. A colony formation assay and a CCK‑8 assay were performed to determine the effect of miR‑192 on cell proliferation, which revealed that miR‑192 suppressed the proliferation of pancreatic β cell lines and insulin secretion. Furthermore, miR‑192 was indicated to promote β‑cell apoptosis. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A recent study has demonstrated that miR‑192 suppresses cell proliferation and induces apoptosis in human rheumatoid arthritis fibroblast‑like synoviocytes and lung cancer (34,35). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present results were consistent with the previous ones, as it was indicated that miR‑192 promoted T1DM through suppressing pancreatic β‑cell proliferation and facilitating cell apoptosis. However, the detailed mechanisms by which miR‑192 affects cell proliferation and apoptosis have remained elusive. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It was then detected whether miR‑192 regulates certain cell cycle‑ and apoptosis‑associated proteins, including cyclin D1, cyclin E1 and caspase‑9, but as it appeared to have no effect the mRNA expression of these genes, it was assumed that miR‑192 regulates the proliferation and apoptosis of pancreatic β cells through other genes / proteins. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX GLP‑1 is a potent insulin secretagogue and promotes glucose‑induced insulin secretion (16,17). As NCI‑H716 cells were previously used to investigate GLP‑1 (29), they were also used in the present study. Furthermore, NIT‑1 cells were employed to investigate the effect of miR‑192 on pancreatic β cells, including their proliferation and apoptosis.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX     CONCLUSION =&gt; In conclusion, to the best of our knowledge, the present study indicates that miR‑192 is upregulated in T1DM and determined the role of miR‑192 in T1DM. miR‑192 was identified as a driver in T1DM. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Mechanisms via which miR‑192 suppresses pancreatic β‑cell proliferation and insulin secretion were provided, and it was demonstrated that miR‑192 suppresses GLP‑1 expression in NCI‑H716 cells. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Additionally, miR‑192 also suppresses cellular proliferation and promotes apoptosis in NIT‑1 cells. It was suggested that miR‑192 is a novel diagnostic biomarker for T1DM. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="data">Identification of Neuroendocrine Stress Response-Related Circulating MicroRNAs as Biomarkers for Type 2 Diabetes Mellitus and Insulin Resistance</td>
<td class="data">This study identified the association between plasma expression
of neuroendocrine stress response-related miRNAs and T2DM as well as IR in an occupational cohort. Based on the differential miRNA expression profile and bioinformatic analysis, six stress-related miRNAs (let-7b, let-7i, miR-142, miR-144, miR-155, and miR-29a) associated with T2DM were selected for qRT-PCR validation. We found that the average expression levels of let-7b, miR-142, miR-144, and miR-29a were significantly different between T2DM patients and healthy controls. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The increased expression of let-7b, miR-144, and miR-29a and decreased expression of miR-142 were significant-independent predictors of T2DM, IFG, and even IR. At the same time, ROC analysis showed that a three-miRNA panel, including let-7b, miR-142, and miR-144 had a high accuracy for diagnosing T2DM. A number of miRNAs have been shown to be important signatures or therapeutic targets in patients with T2DM in circulation and specific tissues (25, 26). miR-184 was reported as a highly regulated miRNA impacting the growth and function of the β-cell. By targets Argonaute2, miR-184 plays adaptive role of the miRNA pathway based on metabolic state (27). Stress-induced overexpression of miR-708 suppressed β-cell proliferation and induced β-cell apoptosis, which provide a novel mechanism of glucose regulation of β-cell function and growth (28). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Comparing to tissue biomarkers, circulating miRNAs are preferred due to easier sampling and testing. Circulating miR-192 and miR-193b were even found significantly increased in the prediabetic state (29). Some other miRNAs have also been identified as biomarkers for diabetic complications, such as plasma miR-152 and diabetic nephropathy, and miR-93 and diabetic retinopathy (30, 31). XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore, circulating miRNAs may help to predict the development and progression of T2DM. Increasing evidence indicates that psychosocial factors facilitate the development and progression of central obesity and T2DM, possibly as the results of increasing insulin resistance (32). In our previous study, the Copenhagen Psychosocial Questionnaire was used to assess job-related psychosocial stress. We found that after adjustment for the influence of cortisol, HOMA-IR was also significantly associated with scales of “demands at work” and “insecurity at work” (6). Psychosocial factors interact with biological mechanisms at several levels in the organisms include neuroendocrine, metabolic, and molecular responses. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Stress hormones influence glucose metabolism by stimulating gluconeogenesis and impairing glucose uptake in peripheral tissues like fat and muscle (8, 33). Activation of stress hormones secretion is mediated by neuronal signals. Repeated stress activates hypothalamic paraventricular nucleus to synthesize CRH, the major regulator of stress responses. Anterior pituitary responds to CRH to produce adrenocorticotropic hormone (ACTH), which is released into the circulation and promotes synthesis and release of glucocorticoids (cortisol in humans) at the level of the adrenal gland (34). The HPA axis controlling cortisol secretion and the SNS both originate in the hypothalamus and they are interlinked, and hyperactivity in one of them can activate the other (35). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our study showed that plasma levels of E, NE, cortisol, and CRH significantly higher in T2DM group than those in control group (P &lt; 0.05). Cortisol and CRH also showed significantly higher levels in the IFG group when compared with controls (P &lt; 0.05). These results provide evidence for the association between chronic stress and T2DM based on an occupational population study. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Elevated activities in both HPA axis and SNS, which were triggered by psychosocial factors have also been reported in individuals with the metabolic syndrome (36). Increased plasma IL-6 levels in T2DM patients and correlation of IL-6 with cortisol in this study maybe another evidence in the pathway between chronic stress and T2DM, since various psychological stressors alone can induce proinflammatory (36, 37). Cellular responsiveness to stress hormone depends on the amount of corresponding receptor protein. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Significant upregulated expression of let-7b and miR-144 in T2DM patients in our study may indicate downregulated expression of their target gene, including ADBR2/ADBR3 (β-adrenoreceptors) and NR3C1 (GR), respectively. Sheng, et al. verified that the protein expression of ADRB3 was regulated by direct binding of let-7b at 3′-UTR (22). In addition, they found that let-7b was negatively correlated with ADRB3 protein level and had a decreased expression in perivascular adipose tissue of hypertensive mice. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Cortisol treatment reduced NR3C1 mRNA levels and increased miR-144 expression in hippocampus and sperm of mice (24). The evidence of NR3C1 as the target of miR-144 can also be obtained from next-generation sequencing (miRTarBase). Positive correlation between let-7b and E/NE, miR-144 and cortisol in the study subjects indicated decreased stress hormone receptor expression, which reflects the negative feedback mechanisms for controlling the magnitude of responses to stress (34). Our previous population-based study showed that chronic stress increase plasma cortisol, which subsequently decrease mRNA expression of GRα and increase of GRβ / GRα mRNA ratio in lymphocyte (14). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX miR-142, which mediated the expression of CRH, showed lower levels in either T2DM or IFG individuals compared with controls. miR-142 also participates in the inflammatory response by regulating the production of IL-6 (23). Both plasma CRH and IL-6 were negatively associated with miR-142 expression in total subjects, which may be explained by the inhibitory effect of miRNA on target genes. Microarray analysis revealed the downregulation miR-142 in the peripheral blood of mice associated with pronounced enhanced oxidative stress (22). XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX miR-29a was reported to be involved in the glucocorticoids signaling pathway (24) and chronic academic stress excessive glucocorticoids reduce the expression of miR-29a (13). The association may partially be explained by receptor gene NR3C1 and CRHR1. Although miR-29a expression significantly associated with T2DM and HOMA-IR, relatively weak correlations exist only between miR-29a and cortisol (r = 0.183) in the total subjects. It is possible that miR-29a regulates glucose metabolism though other pathway. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; It is the first time that we systematically investigated the relationship between plasma expression of neuroendocrine stress response-related miRNAs and T2DM at population level. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The reasonable diagnostic accuracy of miRNA panel (let-7b, miR-142, and miR-144) indicates their clinical value in diagnosing T2DM. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX It is worth noting that significantly altered expression of let-7b, miR-142, miR-144, and miR-29a was found even at the stage of pre-diabetes in this study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These miRNAs were also identified as significant-independent predictors of insulin resistance which is an important component of the pathophysiological processes that underlies the development of T2DM. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The findings of this study support the hypothesis that neuroendocrine stress response-related miRNAs may play a role in the pathogenesis of T2DM and insulin resistance by regulating those target genes which involve neuroendocrine pathways of stress responses, which unveils new targets for the prevention, prediction, and more personalized treatment of neuroendocrine stress-related disorders, including T2DM.  XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="data">Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus</td>
<td class="data">The increase in the incidence of prediabetes in parallel with the rapid increase of T2D prevalence worldwide [1,2] raises an urgent need to develop effective biomarkers for disease detection at an early stage to facilitate future preventive interventions and improve patient’s care [15,16]. microRNAs (miRNAs), a group of small non-coding RNA molecules, have been reported to regulate important cellular processes and are also implicated in many pathological conditions [19]. Being released by cells into the circulation and stalely detected in blood [24], miRNAs have shown promise as prognostic, diagnostic and predictive biomarkers [25–27]. Studies from our group and others have also demonstrated the stability and utility of peripheral blood miRNAs as biomarkers for prediabetes, T2D and other diseases [28,29]. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous studies have demonstrated that aberrant expression of numerous miRNAs including miR-375 and miR-9 influence insulin signaling pathway, insulin resistance and play a major role in T2D [20]. Both miR-375 and miR-9 were previously reported as important regulators of insulin secretion and glucose homeostasis [22,23]. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore, in this study we examined the expression of the diabetes-related miR-375 and miR-9 by TaqMan-based RT-qPCR in peripheral blood of prediabetes patients, T2D patients and non-diabetic healthy individuals and evaluated their suitability as earlier blood biomarkers for detecting prediabetes and T2D. We found that both miR-375 and miR-9 were expressed at higher levels in prediabetes patients and progressively more enriched in T2D patients as compared controls. We also observed that miR-375 expression was significantly higher in T2D patients than in prediabetes patients. On the other hand, although miR-9 expression was observed to be higher in T2D patients than prediabetes patents, it was not however significant. Increased the expression of miR-375 and miR-9 in prediabetes and T2D patients are in agreement with a previous report by Kong et al. [32] showing increased miR-375 and miR-9 in sera from patients with prediabetes and T2D. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In our study, multivariate logistic regression analysis using crude an adjusted models revealed a direct association between miR-375 and miR-9 with the presence of prediabetes and T2D and this association remained significant following adjustment for age, sex, BMI, mean blood pressure, triglyceride, total cholesterol and LDL. These results may suggest an involvement of these two of miR-375 and miR-9 in the pathogenicity of T2D. Additionally, multivariate logistic regression analysis confirmed a significant association of miR-375 but not miR-9, with the development of T2D independently of age, sex, BMI, mean blood pressure, HbA1c, total cholesterol, triglyceride and LDL. These results indicate a possible link between miR-375 and the progression from prediabetes to T2D. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Both miR-375 and 9 are islet-specific microRNAs which expressed at high levels during human pancreatic islet development [21]. Poy et al. [22,33] have demonstrated that miR-375 is abundantly expressed in the pancreatic B–cells and essential for maintaining normal pancreatic cell mass. It functions as a negative regulate of glucose-stimulated insulin secretion through controlling the expression of myotrophin (Mtpn) and phosphoinositide-dependent protein kinase-1 (Pdk1) genes [22,34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Overexpression of miR-375 suppresses insulin secretion, whereas its downregulation enhances insulin release [22]. Therefore, miR-375 is a key player in regulation of insulin release and glucose homeostasis [22]. miR-9 also participates in regulation of insulin secretion through the effect on insulin exocytosis from the pancreas [23]. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Overexpression of miR-9 inversely correlates with glucose stimulated insulin release by directly targeting Onecut2 (OC2), the latter inhibits the expression of Granuphilin / Slp4. While, overexpression of OC2 suppresses Granuphilin transcription [35]. Impaired insulin secretion and action occur both in prediabetes and T2D patients [8,9]. These metabolic abnormalities may precede T2D for years [9,10] and a high percentage of prediabetes patients will progress to clinical T2D [9,10]. Based on the important regulatory roles of miR-375 and miR-9 in insulin secretion, upregulations of miR-375 and miR-9 in blood of prediabetes and T2D patients observed in the current study further support our earlier suggestion that these two miRNAs participation in the pathogenicity of T2D and miR-375 is associated with the T2D progression. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Several epidemiological studies have shown that factor like age, obesity, dyslipidemia, uncontrolled hyperglycemia, hypertension and family history contribute to increased risk of progression to T2D [36,37]. In our study, miR-375 and miR-9, which were significantly elevated in prediabetes and T2D patients, displayed positive correlations with FG and HbA1c both in the two groups of patients. Moreover, miR-375 and miR-9 were positively correlated with mean blood pressure and total cholesterol both in prediabetes and T2D patients and miR-9 was also positively correlated with age and BMI. These results may imply a link between the two miRNAs and the susceptibility to developing T2D. Studies using animal models of diabetes have shown that increased circulating levels of miR-375 serve as useful predictor of diabetes and  B–cell death [38,39]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, the ROC curve analysis revealed that miR-375 discriminated both prediabetes and T2D patients from healthy subjects and also differentiated between prediabetes patients from T2D patients with significant diagnostic ability. Similar to our results, a previous study by Higuchi et al. [40], found a significant increase in the expression of miR-375 in T2D patients and suggested a possible use of this miRNA as a biomarker for T2D. Notably, our results extended these finding and showed that elevated miR-375 expression could be a useful biomarker not only for T2D but also to identify prediabetes patients who are at risk of developing T2D. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Contrary to miR-375, the ROC curve analysis in our study showed lower diagnostic value and borderline significance for miR-9 in discriminating between the three subject groups, suggesting that miR-9 is not a potentially good biomarker for prediabetes and T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Notably, the combination of miR-375 with miR-9 enhanced the predictability to discriminate prediabetes patients from healthy subjects as well as T2D patients from healthy subjects. However, the combined miR-375 with miR-9 did not significantly enhance the predictability to discriminate prediabetes patients from T2D patients. Despite these results, increased miR-9 expression in prediabetes and T2D patients and its correlation with T2D risk factors suggests an association with the susceptibility to T2D. XXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; Our study demonstrated that blood miR-375 and miR-9 were expressed at higher levels in prediabetes and T2D patients compared with non-diabetic healthy subjects and progressively more enriched in T2D patients. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Both miRNAs were directly associated with the presence of prediabetes and T2D independently of known risk factors to T2D and miR-375 was independently associated with the development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX miR-375 and miR-9 were positively correlated with the glycemic status and other T2D risk factors, implying a link between the two miRNAs and the susceptibility to developing T2D. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our study also showed a high diagnostic ability for miR-375 but not miR-9, to distinguish overall patients from control and prediabetes from T2D patients, whereas, the combination of miR-375 with miR-9 -375 showed a good diagnostic ability to discriminate overall patients from controls, indicating that miR-375 alone or in combination with miR-9 could serve as biomarkers for early detection of prediabetes and T2D. XXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="data">Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes</td>
<td class="data">Previous studies have reported that serum and plasma miRNAs may serve as novel biomarkers for various diseases, including T2D (14,17‑21). Furthermore, miRNAs in peripheral whole blood have also shown promise as a novel class of biomarkers for the detection of several types of cancer, such as brain (22) and breast (23) cancer, as well as acute myocardial infarction (24), and other human diseases (25). A study by Karolina et al (30) reported an miRNA marker in the peripheral whole blood of patients with T2D patients and IFG. Their study demonstrated that these blood miRNAs (miR‑144, miR‑146a, miR‑150, miR‑182, miR‑192, miR‑29a, miR‑30d and miR‑320a) may serve as unique biomarkers that are reflective and predictive of T2D (30). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The present study examined the expression levels of T2D‑associated miR‑15a (21) in the peripheral whole blood of patients with T2D, pre‑diabetes individuals (IFG/IGT), and healthy control subjects, and investigated the potential use of blood miR‑15a as a biomarker for predicting T2D and pre‑diabetes. The results demonstrated that blood miR‑15a expression levels were significantly lower in patients with T2D and IFG/IGT individuals, compared with healthy controls. Furthermore, a strong association was observed between lower miR‑15a expression levels and T2D, as well as pre‑diabetes. Notably, this association was not altered following adjustment for known risk factors and certain other biochemical indicators. In a previous population‑based cohort study, Zampetaki et al (21) demonstrated a similar pattern of expression, with circulating plasma miR‑15a expression levels being lower in patients with T2D. The results from the present study extended the association of lower miR‑15a expression levels to pre‑diabetes individuals. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A previous study demonstrated that miR‑15a is implicated in controlling cell cycle and apoptosis in cancer cells (31). The expression levels of miR-15a were shown to inversely correlate with the expression levels of cyclin D1, and negatively regulate those of B‑cell lymphoma 2, a key anti-apoptotic protein (32). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Recently, miR‑15a has been demonstrated to positively regulate and promote insulin biosynthesis by targeting and inhibiting endogenous uncoupling protein‑2 gene expression (33). The overexpression of miR-15a in transfected MIN6 (mouse insulinoma) cells increases insulin secretion, and its suppression decreases insulin levels (33). Therefore, miR‑15a was suggested as an important mediator of β cell function and insulin synthesis, and a possible therapeutic agent for diabetes (33). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The progression from pre‑diabetes (IFG and/or IGT) to early T2D is marked by a decrease in β cell function, and thus a decline in insulin secretion, followed by a failure of β cells to compensate for insulin resistance with hyperinsulinemia that marks the beginning of T2D (3,4). Individuals with IFG have a 20‑30% chance of developing T2D over the following 5‑10 years, and the risk is even higher if individuals with combined IFG and IGT (34,35). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The observation of the present study that blood miR‑15a expression levels were decreased in patients with T2D and IFG/IGT individuals may suggest that miR‑15a expression correlates with disease development. In the present study, the ROC curves revealed that blood miR‑15a levels have a promising ability to distinguish patients with T2D and IFG/IGT individuals from healthy controls, which suggested a potential use of peripheral blood miR‑15 as a biomarker for T2D and pre‑diabetes.  Given that lifestyle interventions may be highly effective in delaying the onset and progression of T2D (7), the evaluation of peripheral blood biomarkers that are capable of distinguishing between patients with T2D and healthy individuals may lead to a novel preliminary screening method to prevent T2D, through the early identification of individuals who are at a higher risk of developing the disease, particularly those individuals with pre‑diabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt;  In conclusion, the results of the present study demonstrated that the expression levels of miR‑15a were significantly lower in the peripheral whole blood of patients with T2D and pre‑diabetes individuals, compared with healthy controls, and that miR-15a in peripheral whole blood may serve as a potential biomarker for the prediction of T2D and pre‑diabetes. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="data">Circulating microRNAs and diabetes: potential applications in medical practice</td>
<td class="data">While the field is still in its infancy, circulating miRNAs appear to offer various potential applications in medical practice as biomarkers of diabetes and associated complications. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Different applications can be envisioned, such as prediction of the disease, detection and monitoring of its complications, evaluation of treatment efficacy and the characterisation of pathogenic traits such as insulin resistance for type 2 diabetes and the autoimmune process for type 1 diabetes.  While improvements in the standardisation of pre-analytical and analytical methods are needed and additional studies on larger cohorts are required before circulating miRNAs can be introduced into medical practice, miRNAs appear to be bona fide biomarkers for diabetes in the future. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Even if the measurement of circulating miRNAs currently has limitations, miRNAs are likely to become useful in the near future. Indeed, one can anticipate that they will complement existing biomarkers, especially in the context of the early identification of individuals at high risk to develop diabetes, and in the detection and the follow-up of diabetic complications. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Indeed, circulating miRNAs contained in vesicles or associated with HDL can be transferred into recipient cells and thus could be involved in cell-to-cell communication [12, 14]. To date, a series of studies has investigated the role of circulating miRNAs as intercellular mediators in diabetic conditions, pointing to possible new mechanisms in diabetes pathogenesis [99–101]. It is clear that the precise potential of circulating miRNAs in complex and multifactorial diseases such as diabetes requires further confirmation both in terms of a biomarker and its involvement in disease mechanisms.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="data">Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention</td>
<td class="data">The discovery of relatively abundant levels of miRNAs in serum / plasma has opened the door to their exploitation as biomarkers for numerous diseases, including cancer or autoimmune diseases (9). To date, there is a scant number  of published reports profiling c-miRNAs in type 2 diabetes (18–20), as well as type 1 or gestational diabetes (21, 22). There are also a number of studies focusing on a single miRNA or a limited number of them (23–25). However, a high-throughput analysis designed to identify a c-miRNA signature in prediabetic patients was still lacking. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX From our data, it is noteworthy that we observed changes in a small percentage of the miRNAs studied in both T2D and prediabetic subjects, suggesting that the alterations of the c-miRNA profile associated with metabolic diseases may not be as evident as those associated with tumors (26). XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another remarkable fact is that we observed only subtle differences in the profile of c-miRNAs between IFG and IGT individuals, although their etiology is different. IFG-type prediabetes, characterized by increased levels of fasting glucose, is thought to be related to defects in the hepato-renal actions of insulin, whereas IGT patients display marked defects in insulin secretion (5). However, both conditions are characterized by insulin secretion defects (the early phase in IFG, and the early and late phases in IGT) and insulin resistance (in the liver in IFG, predominantly in the muscle in IGT) (27). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX On top of that, ethnic differences exist; hence, prediabetic Asian individuals with both IFG and IGT are more prone to defects in insulin secretion (28), whereas Pima Indians with IFG have a more severe defect in early insulin secretion than those with IGT (29). The Insulin Resistance Atherosclerosis Study, including Hispanic and non-Hispanic whites and African American subjects, showed that those with IGT were more insulin resistant than those with IFG (30). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The existence of common pathological mechanisms, although involving different tissues, may explain the moderate differences that we observed in the c-miRNA profile between IFG and IGT subjects. Thus, the validity of our selected miRNAs as biomarkers for prediabetes should be tested before they are applied to other ethnic groups.  XXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We identified two c-miRNAs, miR-192 and miR-193b, which may act as biomarkers for prediabetes. Our results were reproduced in a second cohort of prediabetic subjects and, strikingly, a mouse model of glucose intolerance. Surprisingly, circulating levels of these miRNAs were not altered in T2D patients. The transient nature of the increase of miR-192 and miR-193b during evolution of the disease may reflect the existence of a dynamic state of adaptation of the organism to the new metabolic conditions in the prediabetic state, which might be lost or modified once diabetes is established. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Development of diabetes from a prediabetic status is indeed associated with the acquisition of a novel set of metabolic coordinates, different from the control but also the prediabetic states. The response of the peripheral tissues and the pancreatic islets may thus differ in prediabetes and overt diabetes, hence affecting their combined pattern of miRNA secretion. In this regard, changes in tissue miRNA expression correlating with adaptation processes have been described, such as the increase and posterior decrease of miR-132 in pancreatic islets associated with their pregnancy-driven expansion (31). miR-150 is highly expressed in lymphocytes, where it has a role in regulating differentiation and activation (32). miR-192, on the other hand, is one of the most abundant miRNAs in pancreatic B-cells and liver (33). Changes in circulating miR-192 may act as a biomarker for liver dysfunction under several circumstances, including hepatic steatosis in humans (34). In our samples, miR-192 showed a good correlation with serum TAG and the FLI, a clinical index of steatosis (14), as well as hepatic TAG content in HFD mice. These data could support a role for liver dysfunction in the development of prediabetes in our population, as has been previously shown for others (17). Alternatively, the increase of serum miR-192 in prediabetic  subjects and its posterior return to baseline in overt diabetes might reflect the initial compensation and ulterior failure of the pancreatic B-cells, since it is a B-cell enriched miRNA (33). XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, miR-193b is detected at low levels in plasma or serum and has not been associated with any disease. Interestingly, miR-193b is highly expressed in fat, where it contributes to the differentiation of brown adipocytes as well as decreasing inflammation by targeting chemokine (C-C motif) ligand 2 (35, 36). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Remarkably, these three miRNAs could then convey information regarding the immune system (miR-150), liver and pancreas (miR-192), and fat (miR-193b), which are some of the main tissues involved in the early pathogeny of diabetes. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Exercise has been shown to prevent or delay development of diabetes in at-risk subjects (37), and accordingly, the prediabetic patients included in our study displayed blood glucose levels in the control range after the intervention. It is remarkable that this was accompanied by a partial normalization of miR-192 and miR-193b. Both acute and chronic exercise modify the profile of c-miRNAs in healthy subjects (38). However, circulating miR-192 and miR-193b have not been shown to be regulated by exercise (38). Thus, the decrease that we observed may be related to the partial reversion of the prediabetic phenotype rather than exercise per se. Accordingly, we do not observe a regulation of miR-192 and miR-193b in control subjects after exercise. The profile of c-miRNAs is thus dynamic and correlates with the metabolic phenotype, signaling the presence of disease as well as response to treatment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In summary, we provide evidence for the existence of a c-miRNA signature for prediabetes, which could be used as a new diagnostic tool, as well as to monitor response to treatment.</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="data">The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus</td>
<td class="data">Previous studies have indicated an association between miR-126 and T2DM [23]. The results from the current study extended the association to pre-diabetes (e.g., IFG/IGT subjects). miR-126 is highly enriched in endothelial cells, and plays a pivotal role in maintaining endothelial homeostasis and vascular integrity [25]. It represses two negative regulators of the vascular endothelial growth factor (VEGF) pathway (Sprouty-related protein (SPRED1) and phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2/p85-β)), with an end result of enhanced VEGF signaling [24]. A previous study revealed that shedding miR-126 from endothelial cells could regulate VEGF responsiveness and confer vascular protection in a paracrine manner [26,27]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this study, a RT-qPCR direct serum assay (RT-qPCR-DS) was used to examine serum miR-126. This assay eliminates the RNA extraction step, and therefore, could avoid miRNA loss, minimize human and mechanical errors, and reduce the time and overall cost [28]. Analysis of miR-126 transcripts obtained from the serum of T2DM patients revealed a correlation between T2DM and miR-126 expression. The current study indicated that serum miR-126 could be used to discriminate pre-diabetes from healthy individuals. Also, low miR-126 expression was significantly associated with poor treatment response. ROC analysis showed reasonable sensitivity and specificity of serum miR-126 in distinguishing IFG/IGT and T2DM patients from healthy individuals. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, we also noticed an association of decreased serum miR-126 with high blood glucose; accordingly, the miR-126 content in plasma was reduced in a glucose-dependent fashion. This association suggests that elevated plasma glucose might result in the reduced delivery of miR-126 to monocytes, which in turn contributes to VEGF resistance and endothelial dysfunction. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Serum miR-126 has been linked with numerous diseases, including cancer. However, serum miR-126 has been reported to be both increased and decreased, depending on the type of cancer. miR-126 regulates the expression of several proteins with prominent roles in multiple diseases, including the anti-inflammatory TOM1 (target of Myb1), the growth factor VEGF-A, and the cell cycle regulatory and signaling protein IRS-1 (insulin receptor substrate 1). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt;  In conclusion, our results suggested that circulating miR-126 could be used to distinguish T2DM patients, as well as pre-diabetic subjects from healthy subjects.  XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="data">Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals</td>
<td class="data">DM affects more than 350 million people worldwide in 2011 [1]. The prevalence of DM in Asia has increased significantly in recent years with a disproportionate burden in young and middle-aged population [19]. The situation is considered especially urgent in China because it is becoming a major public health problem. Despite the widely publicized report of 9.7% prevalence for diabetes and 15.5% for prediabetes in the 2007 survey [2], the latest epidemiologic study suggests
that the estimated prevalence has increased to 11.6% for diabetes and 50.1% for prediabetes [3]. Unfortunately, the epidemic of diabetes and prediabetes in China has shown no sign of abating [3]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Due to complex etiology which involves genetics, diet, life style, and environmental factors, DM is posing diagnostic and therapeutic challenges. The existing traditional biochemical markers for DM including levels of glucose, triacylglycerol, cholesterol, lipoproteins, and HbA1c may predict the development of DM a few years prior to disease manifestation. However, these biomarkers are not specific for DM and cannot be used to assess disease susceptibility in the general population. Hence, the discovery of new biomarkers that could be used to identify individuals at risk and thereby provide early intervention to delay the development and progression of DM is urgently needed. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX miRNAs belong to a class of small noncoding RNAs that function as translational repressors by partially pairing to the 3&apos; untranslated region of target mRNAs. The idea of using circulating miRNAs as biomarkers is fairly new and was first proposed for detecting various types of cancer [20]. Circulating miRNAs are very stable and resistant to ribonucleases, freezing/thawing cycles, and other drastic experimental conditions [21]. Consequently, serum or plasma samples can be stored at −20C or −80C for several months without notable degradation of miRNAs, which supports the utility of miRNAs as ideal candidate biomarkers [22]. The miRNA expression profiles in serum samples of prediabetic Han Chinese individuals or T2DM patients have recently been analyzed [23]. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The results showed increased expression of 7 diabetes-related miRNAs (miR9, miR29a, miR30d, miR34a, miR124a, miR146a, and miR375) in T2DM patients compared with pre-diabetic or T2DM susceptible individuals [23]. However, no difference in miRNA expression was observed between individuals with normal glucose tolerance and pre-diabetic individuals, indicating that these serum miRNAs cannot be used for the prediction of susceptibility to T2DM. Zampetaki and colleagues systematically examined the plasma miRNA expression profiles in patients with T2DM by microarray screening and revealed a unique plasma miRNA signature for DM [17]. This pioneer study demonstrates the potential of plasma miRNAs as diagnostic and prognostic biomarkers for T2DM. In this study, we focused on the expression patterns of 5 diabetes-related signature miRNAs identified by Zampetaki’s group and investigated the potential of using plasma miRNAs as a non-invasive tool for blood based prediction of highly susceptible individuals to develop T2DM. We present novel findings that plasma miR-126 level is significantly lower in susceptible individuals and established T2DM patients in comparison to normal individuals, and the decreased miR-126 level is inversely associated with the development of DM. Interestingly, miR-126 expression is not associated with the sex and age of patients. Together, our results support miR-126 as a potential independent risk factor and diagnostic biomarker of susceptible individuals to developing T2DM. Compared to the existing traditional biochemical markers, our proposed miR-126 is more specific to DM and may be able to facilitate early identification of DM risk since its expression level is significantly lower even in the DM susceptible individuals. miRNAs are also more stable and less likely to be affected by diet and physical activities before the blood sample collection. Even though DM is affected by multiple complex factors, such as genetics, environment, diet, and life style, undoubtedly, genetic factor contributes the most to its occurrence. Hence, the identification of genetic markers, such as miRNAs, will yield new and reliable approaches to prevent DM through early identification of individuals at risk. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt;  In conclusion, we have shown that miR-126 is significantly reduced in plasma samples of T2DM susceptible individuals and T2DM patients. These findings suggest that detection of circulating miR-126 can be developed into a non-invasive and rapid diagnostic tool for the prediction of susceptible individuals to developing T2DM.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="data">miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression</td>
<td class="data">Previous studies have consistently demonstrated that there is a progressive deterioration in β-cell function and β-mass in type 2 diabetes [10], and the reduction of β-mass is attributable to the accelerated apoptosis, in which elevated circulating free fatty acids (FFAs) are one of the pivotal predisposing factors responsible for β-cell apoptosis [16;17]. Recent studies highlighted the importance for one particular islet specific miRNA, mir-375, in the regulation of β-cell function and the maintenance of normal pancreatic α- and β-mass [26;27]. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, we further examined the role of mir-375 in the regulation of palmitate-induced β-cell lipoapoptosis. We found that NIT-1 cells, a NOD derived β-cell line, with ectopic mir-375 duplexes are much more susceptible to palmitate induced lipoapoptosis. In contrast, NIT-1 cells are remarkably resistant to palmitate-induced lipoapoptosis once the endogenous mir-375 was suppressed by a specific antisense oligo, 2&apos;-O-Me-375. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our study also demonstrates that the expression levels of V1 protein are inversely associated with β-cell lipoapoptosis. Since V1 could be a target for mir-375 [27], our data suggest that mir-375 probably enhances β-cell lipoapoptosis by downregulation of V1 expressions in β cells. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The cellular population for a particular organ is determined by the balance between the rates of cell division and programmed cell death named apoptosis. Once the apoptosis rate for a particular cell type becomes higher than that of cell replication, a reduction for cell population would occur, which subsequently leads to organ decompensation. Loss of β-mass late in the course of obesity is a typical example that β-cell apoptosis exceeds cell division, which then predisposes to the development of type 2 diabetes. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Lipoapoptosis, a type of apoptosis caused by dysregulated lipid metabolism, has recently been recognized to occur in obesity and aging. Excessive accumulation of long-chain fatty acids is associated with altered leptin liporegulation and, as a result, when non-adipose tissues such as pancreatic islets are exposed to an excess of long-chain fatty acids, the cell would undergo lipoapoptosis. The effect of thermal, hypoxic or cytotoxic factors on apoptosis has been well demonstrated [32], while metabolic causes of programmed cell death, particularly lipoapoptosis, have received less attention. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although recent studies in ZDF (fa/fa) rats suggested an important role for the ceramide pathway in the late destructive phase of lipid overload in the pancreatic β cells [16], the overall underlying mechanisms leading to lipoapoptosis remained poorly understood. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our studies in the current report provided strong evidence indicating a pivotal role for miRNA in the regulation of β-cell lipoapoptosis. Although we are only beginning to appreciate the immense potential of miRNAs as controllers of gene networks, there is already substantial evidence that these small non-coding RNA molecules play a central role in a variety of physiological processes, including tissue differentiation, cell proliferation, and apoptosis. miRNAs are a growing class of non-coding RNAs involved in the regulation of gene expression by translational repression. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Islet-specific mir-375 is originally characterized by Poy and colleagues from analysis of miRNAs in endocrine cell types of the pancreas [27]. Recent functional studies indicated that mir-375 plays an indispensable role in normal glucose homeostasis, β-mass turnover in newborns and adaptive β-cell expansion in response to increasing insulin demand in insulin resistance [26]. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data now provide evidence indicating that mir-375 could also act as a proapoptotic factor implicated in the pathogenesis of β-cell lipoapoptosis. Studies have shown that some evolutionarily conserved proteins characterized in neuronal cells are also present in the pancreatic β cells. V1 is such a protein that is highly expressed in both neuronal cells and pancreatic β cells. V1 (also known as myotrophin) is a 12-kD protein, which was originally identified from the hypertrophied ventricles of spontaneously hypertensive rats and rat cerebellum [33;34]. By 3-dimensional alignment, Knuefermann and colleagues demonstrated that mammalian V1 resembles a truncated IκBα without the signal response domain and PEST sequence [35]. Therefore, V1 was later validated as an anti-apoptotic factor in cardiac myocytes, neuronal cells and fibroblasts [36-38]. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the current study, we further noticed that the expression levels for V1 in NIT-1 cells are inversely associated with palmitate-induced lipoapoptosis, indicating that V1 could also act as an antiapoptotic factor in maintaining β-cell viability. Of important note, we limited our study in the current report to one of the pivotal targets for mir-375, the pancreatic islet-specific V1 protein. It is possible that mir-375 also targets additional factors implicated in the regulation of β-cell apoptosis. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For example, a recent study also suggests that mir-375 could target PDK1 mRNA, a key molecule for PI 3-kinase signaling in the pancreatic β cells [29], which has been demonstrated to be involved in the regulation of cell survival and proliferation [39;40]. Therefore, multiple signaling pathways could be regulated by mir-375, by which mir-375 enhances β-cell lipoapoptosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The modified synthetic anti-miRNA oligonucleotides (AMOs) were found to be useful tools for specific repression of targeted miRNA expressions, thereby helping to unravel the function of miRNAs and their targets. The 2′-O-methyl oligonucleotides have been shown to irreversibly inhibit small RNA function in vitro and in intact cells in a sequence-specific fashion, presumably by stoichiometric binding to RISCs containing the cognate miRNA, and thus preventing interaction with its mRNA targets [41]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similar to antisense-based oligonucleotides (ASOs), AMOs may contribute to the prioritization of pharmaceutical targets and have the potential to eventually progress into a new class of therapeutic agents. Here we have designed a 2′-OMe modified anti-mir-375 oligonucleotide, 2′-O-me-375, and demonstrated its high potency for repression of endogenous mir-375 expressions in NIT-1 cells (Figure 2). As 2′-O-me-375 transfected NIT-1 cells were almost completely protected from palmitate-induced lipoapoptosis (Figure 3), 2′-O-me-375 could be a useful “off-target” reagent for mir-375 with significant implications in both experimental and clinical studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; Impaired β-cell function and possibly β-mass deficit appear to be reversible, particularly at the early stage of disease when the limiting threshold for reversibility of the decreased β-mass has probably not been passed. Our data in the current report indicate that mir-375, a pancreatic islet-specific miRNA, could be a pivotal regulator of lipoapoptosis in the pancreatic β cells.   XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="data">miR-375 maintains normal pancreatic alpha- and beta-cell mass</td>
<td class="data">Our results illustrate an essential role for miR-375 in the establishment of normal pancreatic endocrine cell mass in the postnatal period and the maintenance of glucose homeostasis. The primary consequence resulting from the loss of miR-375 is chronic hyperglycemia caused by a pancreatic B-cell defect, as evidenced by increased B-cell mass, increased glucagon release from isolated islets, elevated fasted and fed plasma glucagon levels, and the increase in downstream effects of glucagon, such as expression of genes regulating gluconeogenesis and hepatic glucose production. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Of note, 375KO mice in the fed state exhibit plasma glucagon levels that are comparable to fasted levels in wild-type mice, further emphasizing the chronic glucagon stimulus in these animals. The hyper-glucagonemia in 375KO mice compared with control littermates is most likely due to the increase in a-cell numbers and a defect in glucose sensing because exocytosis measurements in isolated a-cells in response to direct depolarization was similar in wild-type and mutant mice. The hyperglycemic phenotype of 375KO animals is unlikely due to the moderate (25%) decrease in B-cell mass because this reduction is usually insufficient to cause insulin deficiency and diabetes (30), and amounts of insulin secretion by isolated pancreatic islets from mutant and wild-type mice in response to various concentrations of glucose were similar. Furthermore, insulin levels in the fasted state and during a glucose challenge in 375KO and wild-type littermates were similar, despite a reduced B-cell number in 375KO mice, suggesting that insulin secretion per B cell is enhanced in 375KO mice and that reduction of B-cell mass and increased secretion balance each other in mutant mice.  XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The mechanism by which loss of miR-375 function leads to a reduced B-cell mass is most likely mediated by the cluster of negative growth regulators that are directly regulated by miR-375 and are markedly up-regulated in 375KO animals. The fact that the phenotype is more profound in mice with metabolic stress might indicate that miR-375 targets play a crucial role in B-cell compensation when metabolic demand is increased. The mechanism by which the a-cell number in 375KO pancreata is increased is currently unknown. XXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Two models can be proposed: XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX miR-375 regulates specific target genes in a-cells that are responsible for increased a-cell mass. Alternatively, the increase in a-cell number could be the result of a compensatory response to altered B-cell mass and function or to the chronic hyperglucagonemia, which in some models is associated with a-cell hyperplasia (31, 32). Mice bearing a conditional deletion of dicer, an enzyme required for miRNA processing, during pancreas development exhibit defects in all pancreatic cell lineages, abnormal islet architecture, and a profound reduction in pancreatic B cells (8). XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Mutant 375KO mice only partially mimic this phenotype, suggesting that miR-375 alone is not responsible for the marked developmental defect in B-cell growth and differentiation and that other miRNAs, which are expressed in endocrine pancreatic precursor cells, must be responsible for the observed phenotype of the Pdx-Cre/dicer mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, it is interesting that miR-375 plays a significant role in the hypertrophic growth response of pancreatic islets to metabolic stress. Expression levels of miR-375 are aberrant in obese mice, indicating that they contribute to increased B-cell mass in insulin resistance. Ablation of miR-375 expression in obese mice leads to a profound loss of  B-cells, metabolic decompensation, and premature death. Under these conditions, a-cell mass is not affected, suggesting that miR-375 has a less prominent role in a-cells, which are not under particular metabolic or cellular stress in hyperglycemic / insulin resistant conditions. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt;  Increasing evidence implicates miRNAs as an essential component mediating responses to cellular stress. For instance, tissue-enriched miRNAs in the heart, such as miR-1, miR-208, and miR-133, have been shown to regulate the hypertrophic proliferative activity in response to a variety of stresses, and miR-126 affects survival after induction of a myocardial infarction (7, 12, 33). . XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="data">Serum microRNAs are promising novel biomarkers</td>
<td class="data">The results of this study clearly uphold our basic hypothesis that microRNAs are present in bodily fluids and represent useful clinical biomarkers. Importantly, we have developed reliable methods for extracting microRNAs from bodily fluids and for evaluating their abundance. Moreover, we have demonstrated that microRNA serum levels reflect physiological conditions, such as pregnancy, and can even be used to determine pregnancy stage. We identified previously a large subset of microRNAs that are expressed almost exclusively in the placenta [10,20] and found that a sizeable number of these are primate-specific [10]. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The biological role of these placental microRNAs remains unclear, although it is tempting to speculate that they contribute to specific morphological placental features characteristic of primates and key to their evolution [21]. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Here we show that many of these microRNAs are found in maternal serum, at levels that increase with gestational age. The recently reported, distinctive expression of microRNAs in the placenta in association with preeclampsia [24] highlights the possibility that serum levels of particular microRNAs may serve as future diagnostic biomarkers for preeclampsia. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This proof of concept study reveals the potential of body fluid microRNAs to serve as practicable molecular markers for diverse physiological and pathological conditions, especially those where microRNAs have already been found to play a critical role, such as cancer. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Moreover, we demonstrate here the ease and reliability of determining body fluid microRNA profiles and thus, pave the way for their wide application, both in the research laboratory and in the clinic. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
</tbody>
</table>
</div>
</div>
</body>
</html>
